Keyword: Clovis Oncology

wall street bull color

Tesaro

If Axovant was a textbook example of how not to create a company around somebody else’s castoffs, Tesaro was a model of how to do it right. The startup came to life in 2010 with a trio of cancer drug business veterans and $20 million stumped up by New Enterprise Associates.

Gritstone Oncology

Gristone Oncology, a biotech-medtech crossover, is working to apply next-generation sequencing, bioinformatics and algorithms to the creation of new cancer immunotherapies.
breast cancer

21. Rubraca

With an accelerated approval ahead of its February 2017 PDUFA date, Clovis Oncology’s Rubraca is set to launch and challenge AstraZeneca’s Lynparza.